• Explore /
  • Poster
  • / Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: A prospective, single-arm, phase II trial.

Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: A prospective, single-arm, phase II trial.

Abstract Poster

Authors

null

Hongyu Pan

The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Shanghai, China

Hongyu Pan , Liuyu Zhou , Zhuo Cheng , Cheng Yang , Jin Zhang , Ningjia Shen , Hongbin Ma , Yao Li , Riming Jin , Weiping Zhou , Dong Wu , Wen Sun , Ruoyu Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Local-Regional Disease

Clinical Trial Registration Number

ChiCTR2000036385

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4118)

DOI

10.1200/JCO.2024.42.16_suppl.4118

Abstract #

4118

Poster Bd #

98

Abstract Disclosures

Similar Posters

First Author: Jia-Yi Wu

First Author: Yaobin Lin

First Author: Arndt Vogel

First Author: Peng Jin